Objectives To quantify and compare potential benefits (subjective reports of sleep variables)
and risks (adverse events and morning-after psychomotor impairment) of short term …

Background: Cholinesterase inhibitors (ChEIs) are the only drugs marketed for the treatment
of Alzheimer's disease. Despite numerous randomized controlled trials, the efficacy and …

… The number of datasets (k) included in each estimate is also depicted … IL-1β levels were
not altered in treatment responders (g = 0.617, k = 3, P = 0.407), while peripheral levels of this …

BACKGROUND: Major depression occurs in 4.4% to 20% of the general population. Studies
suggest that major depression is accompanied by immune dysregulation and activation of …

… The ES estimate was high (g = 1.720; P = 0.012), although a limited number of studies
were included in this meta-analysis (k = 5). Heterogeneity was large (I 2 = 95.3%), and no …

BACKGROUND: Studies suggest that inflammation is involved in the neurodegenerative
cascade leading to Alzheimer's disease (AD) pathology and symptoms. This study sought to …

… Krista Lanctôt has had research support and/or speaker’s honoraria from Abbvie Canada,
Lundbeck Canada Inc., Pfizer Canada Inc., Janssen Ortho, and Rocheand Wyeth. Dr. …

Objectives Increasing evidence suggests that inflammation is involved in Alzheimer’s disease
(AD) pathology. This study quantitatively summarised the data on peripheral inflammatory …

Alzheimer's disease and related dementias (ADRDs) are a global crisis facing the aging
population and society as a whole. With the numbers of people with ADRDs predicted to rise …

Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are widespread and disabling.
This has been known since Dr. Alois Alzheimer's first case, Frau Auguste D., presented …